Press release
March 7, 2018
Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance
Vaxart, Inc. (VXRT)
Issued Claims Cover High Yield Production Process of Phase 2 Antiviral SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT) a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the